199 completed, 23 recruiting, 22 terminated, 21 unknown. 105 Phase 1, 80 Phase 2, 46 Phase 3, 15 Not applicable, 3 Phase 4.
Follow Respiratory Syncytial Virus Infections: new trials by email Literature Review of Respiratory Syncytial Virus Infections trials Research Report on Respiratory Syncytial Virus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults Bivalent RSV Vaccine (IN006), Placebo - Respiratory Syncytial Virus Infections | Phase 1 | Not yet recruiting | Shenzhen Shenxin Biotechnology Co., Ltd | 200 | 2026-12-01 | 2026-04-13 |
| Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection. SYH2066, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 80 | 2026-11-13 | 2026-10-20 |
| Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region Vaccination Coverage Among Pregnant Women | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1605 | 2026-11-01 | 2026-10-20 | |
| Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset ABRYSVO - Respiratory Syncytial Virus Infections | Not yet recruiting | Pfizer | 1 | 2026-10-15 | 2026-09-24 | |
| The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation Clesrovimab - RSV Infection | Phase 4 | Not yet recruiting | Emory University | 24 | 2026-09-01 | 2026-09-17 |
| Internal Jugular Vein Respiratory Variability as a Marker of Disease Severity in Infant Bronchiolitis Point-of-Care Ultrasonography - Acute Bronchiolitis, Viral Bronchiolitis | Not yet recruiting | Eskisehir Osmangazi University | 120 | 2026-09-01 | 2026-08-21 | |
| A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus zelicapavir, Placebo - RSV Infection, RSV | Phase 2 | Recruiting | Enanta Pharmaceuticals, Inc | 150 | 2026-07-09 | 2026-07-20 |
| Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections SARS CoV 2 Infection, RSV Infections | Not yet recruiting | Fabiana Sherine Ganem dos Santos | 150 | 2026-07-01 | 2026-06-11 | |
| Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant) - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Recruiting | Ab&B Bio-tech Co., Ltd.JS | 470 | 2026-05-14 | 2026-05-27 |
| Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France saliva sampling, Nasopharyngeal swab - Respiratory Tract Infections (RTI), Influenza -Like Illness | Recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 25000 | 2026-05-14 | 2026-08-03 | |
| Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital Bronchiolitis, Acute Bronchiolitis | Not yet recruiting | Assiut University | 65 | 2026-05-01 | 2026-04-01 | |
| Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3 - Respiratory Syncytial Virus (RSV), Influenza A(H5N1) | Phase 1 | Recruiting | Sanofi | 570 | 2026-04-15 | 2026-05-08 |
| Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants Respiratory Syncytial Virus Infection, Bronchiolitis | Not yet recruiting | Phuc Huu Phan | 250 | 2026-04-01 | 2026-02-18 | |
| A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children SIM0916, SIM0916 Placebo - Respiratory Syncytial Virus Infection | Phase 3 | Recruiting | Simcere Pharmaceutical Co., Ltd | 498 | 2026-03-11 | 2026-04-02 |
| A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection. Ziresovir (AK0529), Placebo - Respiratory Syncytial Virus Infections | Phase 2 / Phase 3 | Recruiting | Shanghai Ark Biopharmaceutical Co., Ltd. | 290 | 2026-03-03 | 2026-06-22 |
| RSV-Positive Children <5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV Respiratory Syncytial Virus Infection, Acute Bronchiolitis Due to Respiratory Syncytial Virus | Not yet recruiting | Eskisehir Osmangazi University | 4000 | 2026-01-01 | 2026-01-16 | |
| Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá RSVpreF vaccine (Abrysvo) and Nirsevimab (Beyfortus) or unexposed - Respiratory Syncytial Virus Infections, Severe Acute Respiratory Infection | Active not recruiting | Bogotá District Health Secretariat | 1097 | 2026-01-01 | 2026-08-06 | |
| Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals Remdesivir, Survey Administration, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2025-12-23 | 2026-10-01 |
| A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease S-337395, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Recruiting | Shionogi | 192 | 2025-12-11 | 2026-10-21 |
| A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease RSVPreF3 OA vaccine, Placebo - Respiratory Syncytial Virus Infections | Phase 3 | Active not recruiting | GlaxoSmithKline | 750 | 2025-10-29 | 2026-08-03 |
Showing 20 of 302. Sign in to see all of them.
Respiratory Tract Infections (18) · Influenza, Human (17) · COVID-19 (16) · Bronchiolitis (15) · Virus Diseases (11) · Infections (9) · Pneumonia (7) · Asthma (6) · Paramyxoviridae Infections (4) · Premature Birth (4) · Bronchiolitis, Viral (3) · Bronchopulmonary Dysplasia (3) · Respiratory Sounds (3) · Whooping Cough (3)
Mononegavirales Infections (302) · Pneumovirus Infections (302) · RNA Virus Infections (301) · Paramyxoviridae Infections (298) · Infections (293) · Virus Diseases (291) · Respiratory Tract Diseases (59) · Lung Diseases (39) · Respiratory Tract Infections (37) · Bronchial Diseases (20) · Lung Diseases, Obstructive (19) · Coronaviridae Infections (17) · Nidovirales Infections (17) · Orthomyxoviridae Infections (17) · Bronchitis (16)
Saline Solution (9) · EDP-938 (8) · Palivizumab (7) · nirsevimab (7) · sisunatovir (7) · ziresovir (7) · 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (6) · JNJ-53718678 (5) · presatovir (5) · Adjuvants, Pharmaceutic (4) · Midazolam (4) · Respiratory Syncytial Virus Vaccines (4) · abrysvo (4) · gontivimab (4) · motavizumab (4)
GlaxoSmithKline (39) · National Institute of Allergy and Infectious Diseases (NIAID) (23) · Enanta Pharmaceuticals, Inc (14) · Pfizer (13) · MedImmune LLC (10) · Sanofi Pasteur, a Sanofi Company (9) · Gilead Sciences (8) · Shanghai Ark Biopharmaceutical Co., Ltd. (7) · Alios Biopharma Inc. (5) · Bavarian Nordic (5) · Hospices Civils de Lyon (5) · AbbVie (prior sponsor, Abbott) (4) · Ablynx, a Sanofi company (4) · AstraZeneca (4) · Imperial College London (4)
United States (143) · United Kingdom (53) · Australia (43) · Spain (38) · Canada (30) · China (30) · France (30) · Belgium (28) · Japan (28) · South Africa (27) · Germany (24) · Poland (22) · Finland (21) · Italy (20) · Argentina (18)
Ruth A. Karron, MD (9) · Oliver Medzihradsky, MD MPH MS (3) · Coleen Cunningham, MD (2) · D. Nigel Thomas, Ph.D. (2) · Genevieve Losonsky, MD (2)
PMID 31951765, PMID 34774184, PMID 38921800, PMID 29401325, PMID 29509911, PMID 29509929, PMID 31211158, PMID 37468530, PMID 38902186, PMID 14722149, PMID 15188713, PMID 15356783, PMID 16390959, PMID 17156899, PMID 17541638, PMID 18477402, PMID 18676537, PMID 19196675, PMID 19782998, PMID 20008423, PMID 20492042, PMID 20525274, PMID 20851929, PMID 21318606, PMID 21343842, PMID 21926667, PMID 22203430, PMID 22335500, PMID 22354452, PMID 22546928, PMID 22553238, PMID 22943074, PMID 23089688, PMID 23153449, PMID 23734183, PMID 23861694, PMID 23989104, PMID 24080520, PMID 24086113, PMID 24367040, PMID 24799541, PMID 24941423, PMID 25140957, PMID 25714161, PMID 25970287, PMID 26227333, PMID 26237402, PMID 26268313, PMID 26510727, PMID 26580997
2023 (9), 2019 (6), 2014 (5), 2016 (5), 2018 (5), 2015 (2), 2017 (2), 2025 (1), 5UM1AI148684-04 (1), R01AI179874 (1), R01HD105678 (1)